Levicept to Present Phase II Data for LEVI-04 at Key Healthcare Conferences

  • Levicept will present Phase II trial data for LEVI-04 at IASP World Congress on Pain (Oct 26-30) and ACR Convergence (Nov 6-11).
  • New analyses from the Phase II trial (NCT05618782) will be shared, following previously published results in The Lancet.
  • Levicept’s leadership will attend the Jefferies Global Healthcare Conference (Nov 16-19) for investor meetings.
  • LEVI-04 is a first-in-class non-opioid analgesic for osteoarthritis, with potential disease-modifying properties.

Levicept’s participation in major healthcare conferences underscores the strategic importance of its Phase II data for LEVI-04, a potential breakthrough in osteoarthritis treatment. The focus on both clinical and investor forums highlights the dual challenge of scientific validation and market positioning in a competitive biotech landscape. If successful, LEVI-04 could become the first new systemic treatment for OA in over two decades, addressing a significant unmet need in pain management.

Clinical Validation
Whether the new analyses from the Phase II trial will further validate LEVI-04’s potential as a disease-modifying treatment for osteoarthritis.
Investor Sentiment
How investor meetings at the Jefferies conference will impact Levicept’s valuation and funding prospects.
Regulatory Pathway
The pace at which Levicept can advance LEVI-04 toward Phase III trials and eventual regulatory approval.